Best Practices Workshop and the 6th MAQC Project Meeting

Everyone is encouraged to attend the following two related meetings:

A. "*Best Practices and Development of Standards for the Submission of Genomic Data to the FDA*", co-sponsored by FDA/DIA/PhRMA/BIO, Washington Marriott Hotel, Washington, DC, Nov. 27-28, 2006. Final program and updates are available at http://www.diahome.org/product/12225/06036.pdf. MAQC Phase II participants are highly encouraged to attend the "*Best Practices*" workshop.

B. *The 6th MAQC Project Meeting*: MAQC Phase II Efforts on Predictive Signatures
Date: Wednesday, Nov 29, 2006 (plus Nov 28, 3:00 PM – 5:00 PM, see notice below)
Time: 9:00 AM to 4:00 PM ET
Place: U.S. Food and Drug Administration, Room 2031, Central Shared Use Building, 10903 New Hampshire Avenue, Silver Spring, MD 20903-0002, USA.
Topics:

1. To review the progresses of the three Working Groups of MAQC Phase II (Clinical, Toxicogenomics, and Titration);
2. To decide on the data sets to be used in Phase II;
3. To develop a detailed working plan for each Phase II Working Group.

Detailed meeting agenda will be distributed as soon as it is available.

Important notice: To ensure that we'll have enough time to discuss MAQC Phase II on Nov. 29, the three Working Groups (Clinical, Toxicogenomics, and Titration) will present their progresses on Tue, **Nov. 28, 3:00 PM to 5:00 PM ET** at the same conference room reserved for the Best Practices workshop that will end at 2:00 PM, Nov. 28.

Thank you and best regards,

-Leming

Leming Shi, Ph.D.
National Center for Toxicological Research (NCTR)
U.S. Food and Drug Administration (FDA)
3900 NCTR Road
Jefferson, Arkansas 72079
U.S.A.
Tel: +1-870-543-7387
Fax: +1-870-543-7854
Leming.Shi@fda.hhs.gov
http://edkb.fda.gov/MAQC/